1. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Cancer 449:2112-2135, 1982.

2. Harris NL, Jaffe ES, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.

3. Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting—Airlie House, Virginia. J Clin Oncol 17:3835-3849, 1999.

4. Jaffe ES, Harris NL, Stein H, et al.: Tumours of haematopoietic and lymphoid tissues. In: World Health Organization Classification of Tumours: Pathology & Genetics. Lyon, France: IARC Press, 2001.

5. Ott G, Katzenberger T, Lohr A, et al.: Cytomorphologic, immunohistochemical, and cytogenetic profiles of fol-licular lymphoma: 2 types of follicular lymphoma grade 3. Blood 99:3806-3812, 2002.

6. Chau I, Jones R, Cunningham D, et al.: Outcome of fol-licular lymphoma grade 3: is anthracycline necessary as front-line therapy? Br J Cancer 89:36-42, 2003.

7. Hans CP, Weisenburger DD, Vose JM, et al.: A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101:2363-2367, 2003.

8. Hsi ED, Mirza I, Lozanski G, et al.: A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences. Arch Pathol Lab Med 128:863-868, 2004.

9. Shipp MA, Harrington DP, Anderson JR, et al.: Development of a predictive model for aggressive lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993.

10. Solal-Celigny P, Roy P, Colombat P, et al.: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004.

11. Cheson BD, Horning SJ, Coiffier B, et al.: Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17: 1244-1253, 1999.

12. Löpez-Guillermo A, Montserrat E, Bosch F, et al.: Applicability of the International Prognostic Index for aggressive lymphomas in patients with low-grade lymphoma. J Clin Oncol 12:1343-1348, 1994.

13. Hermans J, Krol ADG, van Groningen K, et al.: International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86:1460-1463, 1995.

14. Mac Manus M, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282-1290, 1996.

15. Advani R, Rosenberg SA, Horning SJ: Stage I and II fol-licular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 22:1454-1459, 2004.

16. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 311:1471-1475, 1984.

17. Dana BW, Dahlberg S, Nathwani BN, et al.: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993.

18. Young RC, Longo DL, Glatstein E, et al.: The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 25: 11-16, 1988.

19. Brice P, Bastion Y, Lepage E, et al.: Comparison of low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Group D'Etude des Lymphomes Folliculares. J Clin Oncol 15:1110-1117, 1997.

20. Kimby E, Björkholm M, Gahrton G, et al.: Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 5:567-571, 1994.

21. Hochster HS, Kim K, Green MD, et al.: Activity of flu-darabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28-32, 1992.

22. Redman JR, Cabanillas F, Velasquez WS, et al.: Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 10:790-794, 1992.

23. Zinzani PL, Lauria F, Rondelli D, et al.: Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 4:575-578, 1993.

24. Pigaditou A, Rohatiner AZS, Whelan JS, et al.: Fludarabine in low-grade lymphoma. Semin Oncol 20:24-27, 1993.

25. Hiddemann W, Unterhalt M, Pott C, et al.: Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-grade Non-Hodgkin's Lymphoma Study Group. Semin Oncol 20:28-31, 1993.

26. Solal-Celigny P, Brice P, Brousse N, et al.: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14:514-519, 1996.

27. Flinn IW, Byrd JC, Morrison C, et al.: Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96:71-75, 2000.

28. Velasquez WS, Lew D, Grogan TM, et al.: Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 21:1996-2003, 2003.

29. Zinzani PL, Pulsoni A, Perrotti A, et al.: Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 22:2654-2661, 2004.

30. Merigan TC, Sikora K, Breeden JH, et al.: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med 299:1449-1553, 1978.

31. Foon KA, Sherwin SA, Abrams PG, et al.: Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 311:1148-1152, 1984.

32. O'Connell MJ, Colgan JP, Oken MM, et al.: Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 4:128-136, 1986.

33. Solal-Celigny P, Lepage E, Brousse N, et al.: Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 329:1608-1614, 1993.

34. Solal-Celigny P, Lepage E, Brousse N, et al.: A doxoru-bicin-containing regimen with or without interferon alpha-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the GELF 86 trial. J Clin Oncol 16:2332-2338, 1998.

35. Smalley RV, Andersen JW, Hawkins MJ, et al.: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336-1341, 1992.

36. Aviles A, Duque G, Talavera A, et al.: Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 20:495-499, 1996.

37. Unterhalt M, Hermann R, Koch P, et al.: Long term interferon alpha maintenance prolongs remission duration in advanced low grade lymphomas and is related to the efficacy of initial cytoreductive therapy. Blood 88:453a, 1996. Abstract 1801.

38. Hagenbeek A, Carde P, Meerwaldt JH, et al.: Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 16:41-47, 1998.

39. Fisher RI, Dana BW, LeBlanc M, et al.: Alpha-interferon consolidation following intensive chemotherapy does not prolong the failure-free survival of patients with low grade non-Hodgkin's lymphoma: results of SWOG-8809, a randomized phase III study. J Clin Oncol 18:2010-2016, 2000.

40. Chisesi T, Congiu M, Contu A, et al.: Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) in low-grade non-Hodgkin's lymphoma: an interim report of a randomized study. Eur J Cancer 27:S31-S33, 1991.

41. Price CGA, Rohatiner AZS, Steward W, et al.: Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: preliminary results of a randomized trial in progress. Eur J Cancer 27:S34-S36, 1991.

42. Peterson BA, Petroni G, Oken MM, et al.: Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low grade lymphomas: a preliminary report of an intergroup trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol 12:366, 1993. Abstract 1240.

43. Arranz R, Garcia-Alfonso P, Sobrino P, et al.: Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 16:1538-1546, 1998.

44. Rohatiner AZS, Gregory W, Peterson B, et al.: A metaanalysis (MA) of randomised trials evaluating the role of interferon (IFN) as treatment for follicular lymphoma (FL). Proc Am Soc Clin Oncol 17:4a, 1998. Abstract 11.

45. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998.

46. Piro LD, White CA, Grillo-Lopez AJ, et al.: Extended rit-uximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10:655-661, 1999.

47. O'Brien SM, Kantarjian H, Thomas DA, et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001.

48. Byrd JC, Murphy T, Howard RS, et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lym-phocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001.

49. Colombat P, Salles G, Brousse N, et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patents with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97: 101-106, 2001.

50. Hainsworth JD, Lichty S, Burris HA III, et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20: 4261-4267, 2002.

51. Demidem A, Lam T, ALas S, et al.: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997.

52. Johnson TA, Press OW: Synergistic cytotoxicity of iodine-131-anti-CD20 antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer 85: 104-112, 2000.

53. Czuczman MS, Grillo-Lopez AJ, White CA, et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999.

54. Czuczman M, Grillo-Lopez AJ, LoBuglio AF, et al.: Patients with low-grade NHL treated with rituximab + CHOP experience prolonged clinical and molecular remission. Blood 102: Abstract 1493, 2003.

55. Hiddemann W, Dreyling M, Forstpointner R, et al.: Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma—results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 102: Abstract 352, 2003.

56. Marcus R, Imrie K, Belch A, et al.: An international multi-centre, randomized, open-label phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV fol-licular non-Hodgkin's lymphoma. Blood 102: Abstract 87, 2003.

57. Czuczman MS, Fallon A, Mohr A, et al.: Phase II study of rituximab plus fludarabine in patients (pts) with low-grade follicular lymphoma (LGL): final report. Blood 98:601a, 2001. Abstract 2518.

58. Martinelli G, Laszlo D, Mancuso P, et al.: Rituximab plus chlorambucil in low-grade non Hodgkin's lymphomas (NHL): clinical results of a phase II study. Blood 100:777a, 2002. Abstract 3073.

59. Sacchi S, Tucci A, Merli F, et al.: Phase II study with flu-darabine and cyclophosphamide plus rituximab (FC+R) in relapsed follicular lymphoma patients. Blood 100: 572a, 2002. Abstract 2246.

60. Gregory SA, Venugopal P, Adler S, et al.: Combined flu-darabine, mitoxantrone and rituximab achieves a high response rate as initial treatment for advanced low grade non-Hodgkin's lymphoma (LGNHL). Blood 100:362a, 2002. Abstract 1401.

61. Vitolo U, Boccomini C, Ladetto M, et al.: High clinical and molecular response rate in elderly patients with advanced stage follicular lymphoma treated at diagnosis with a brief chemo-immunotheraepy FND + rituximab. Blood 100:359a, 2002. Abstract 1392.

62. Zinzani PL: A multicenter randomized trial of fludara-bine and mitoxantrone (FM) plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma. Blood 100:93a, 2002. Abstract 344.

63. Rummel MJ, Kim SZ, Chow KU, et al.: Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantle cell lymphomas. Blood 102:104a, 2003. Abstract 353.

64. Ghielmini M, Schmitz SF, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with weekly X 4 schedule. Blood 103:4416-4423, 2004.

65. Hochster HS, Weller E, Ryan T, et al.: Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc Am Soc Clin Oncol 22:558s, 2004. Abstract 6502.

66. Davis TA, Grillo-Lopez AJ, White CA, et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreat-ment. J Clin Oncol 18:3135-3143, 2000.

67. Hainsworth JD, Litchy S, Greco FA: Scheduled ritux-imab maintenance therapy versus rituximab retreat-ment at progression in patients with indolent non-Hodgkin's lymphoma (NHL) responding to single-agent rituximab: a randomized trial of the Minnie Pearl Cancer Research Network. Blood 102: Abstract 231, 2003.

67a. Van Oers MHJ, Van Glabbeke M, Teodorovic I, et al.: Chimeric anti-CD20 monoclonal antibody (Rituximab; Mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma. Final analysis of a phase III randomized intergroup clinical trial. Blood 106(Part 1): 107a (abstract 353), 2005.

68. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947, 2003.

69. Bohen SP, Troyanskaya OG, Alter O, et al.: Variation in gene expression patterns in follicular lymphoma and response to rituximab. Proc Natl Acad Sci USA 100: 1926-1930, 2003.

70. Mounier N, Briere J, Gisselbrecht C, et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284, 2003.

71. Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554-3561, 2002.

72. Lundin J, Österborg A, Brittinger G, et al.: CAMPATH-1H monoclonal antibody therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. J Clin Oncol 16:3257-3263, 1998.

73. Leonard JP, Coleman M, Ketas JC, et al.: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21: 3051-3059, 2003.

74. Emmanouilides C, Leonard J, Schuster SJ, et al.: Multicenter, phase 2 study of combination antibody therapy with epratuzumab plus rituximab in recurring low-grade NHL. Blood 102: Abstract 233, 2003.

75. Czuczman M, Witzig TE, Vose JM, et al.: Results of a phase I/II multicenter trial of galiximab (IDEC-114, anti-CD80 antibody) therapy for relapsed or refractory follicular lymphoma. Blood 102:647-648a, 2003. Abstract 2393.

76. Gordon LI, Moore JO, Cheson BD, et al.: Phase I results from a multicenter trial of galiximab (anti-CD80 antibody, IDEC-114) in combination with rituximab for the treatment of follicular lymphoma. Blood 102:307b, 2003. Abstract 4951.

77. Link BK, Wang H, Byrd JC, et al.: Phase I trial of humanized 1D10 (Hu1D10) monoclonal antibody targeting class II molecules in patients with relapsed lymphoma. Proc Am Soc Clin Oncol 19:24a, 2000. Abstract 86.

78. Link BK, Kahl B, Czuczman M, et al.: A phase II study of Remitogen™ (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicu-lar, small lymphocytic, or marginal zone/MALT B-cell lymphomas. Blood 98:606a, 2001. Abstract 2540.

79. Stein R, Qu Z, Chen S, et al.: Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 10: 2868-2878, 2004.

80. Cheson BD: Radioimmunotherapy of non-Hodgkin's lymphomas. Blood 101:391-398, 2003.

81. Wiseman GA, Gordon LI, Multani PS, et al.: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336-4342, 2002.

82. Witzig TE, White CA, Wiseman GA, et al.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999.

83. Witzig TE, Flinn IW, Gordon LI, et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002.

84. Witzig TE, Gordon LI, Cabanillas F, et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002.

85. Gordon LI, Molina A, Witzig T, et al.: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 103:4429-4431, 2004.

86. Kaminski MS, Zelenetz AD, Press OW, et al.: Pivotal study of Bexxar (Iodine I-131 tositumomab) for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001.

87. Kaminski MS, Tuck M, Regan D, et al.: High response rate and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine I-131 tositumomab (Bexxar©). Blood 100:356a, 2002. Abstract 1381.

88. Press OW, Unger JM, Braziel RM, et al.: A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine

I 131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Southwest Oncology Group protocol S9911. Blood 102:1606-1612, 2003.

89. Gopal AK, Gooley TA, Maloney DG, et al.: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 102:2351-2357, 2003.

90. Bennett JM, Kaminski MS, Knox SJ, et al.: Assessment of treatment-related myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML) in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) treated with tositumomab and iodine-131 tositumomab (the Bexxar therapeutic regimen). Blood 102: Abstract 91, 2003.

91. Witzig TE, White CA, Gordon LI, et al.: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003.

92. Kaminski M, Bahm V, Estes J, et al.: Tolerance of treatment subsequent to frontline Bexxar™ (tositumomab and iodine I131 tositumomab) in patients (Pts) with fol-licular lymphoma. Blood 98:603a, 2001. Abstract 2526.

93. Ansell SM, Ristow KM, Habermann TM, et al.: Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with 90Yttrium ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20:3885-3890, 2002.

94. Waters JS, Webb A, Cunningham D, et al.: Phase I and pharmacokinetic study of bcl-2 antisense oligonu-cleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18:1809-1811, 2000.

95. Hsu FJ, Caspar C, Czerwinski D, et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long term results of a clinical trial. Blood 89:3129-3135, 1997.

96. Kath R, Blumenstengel K, Fricke HJ, et al.: Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127:48-54, 2001.

97. Schwänen C, Karakas T, Begmann L: Bendamustine in the treatment of low-grade non-Hodgkin's lymphomas. Onkologie 23:318-324, 2000.

98. Weidmann E, Kim SZ, Rost A, et al.: Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 13:1285-1289, 2002.

99. Bremer K: High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas. J Cancer Res Clin Oncol 128:603-609, 2002.

100. Richardson PG, Barlogie B, Berenson JR, et al.: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003.

101. Goy A, Younes A, McLaughlin P, et al.: A phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005.

102. O'Connor OA, Wright J, Moskowitz C, et al.: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005.

103. Freedman AS, Nadler LM: Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? J Clin Oncol 11:1841-1843, 1993.

104. Freedman AS, Gribben JG, Neuberg D, et al.: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma. Blood 88: 2780-2786, 1996.

105. Rohatiner AZS, Johnson PWM, Price CGA, et al.: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12:1177-1184, 1994.

106. Freedman AS, Neuberg D, Mauch P, et al.: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999.

107. Schouten HC, Qian W, Kvaloy S, et al.: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 21:3918-3927, 2003

108. Darrington DL, Vose JM, Anderson JR, et al.: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527-2534, 1994.

109. Miller JS, Arthur DC, Litz CE, et al.: Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 83:3780-3788, 1994.

110. Stone RM, Neuberg D, Soiffer R, et al.: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12:2535-2542, 1994.

111. Friedberg JW, Neuberg D, Stone RM, et al.: Outcome in patients with myelodysplastic syndrome after autolo-gous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 17:3128-2135, 1999.

112. van Besien KW, Khouri IF, Giralt S, et al.: Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 13:1096-1102, 1995.

113. van Besien K, Sobocinski KA, Rowlings PA, et al.: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836, 1998.

114. Ratanatharathorn V, Uberti J, Karanes C, et al.: Prospective comparative trial of autologous versus allo-geneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84:1050-1055, 1994.

115. Haioun C, Lepage E, Gisselbrecht C, et al.: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 12: 2543-2551, 1994.

116. Khouri IF, Keating M, Korbling M, et al.: Transplant-lite: induction of graft-versus malignancy using flu-darabine-based nonablative chemotherapy and allo-geneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817-2824, 1998.

117. Khouri IF, Saliba RM, Giralt SA, et al.: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595-3599, 2001.

118. Faulkner RD, Craddock C, Byrne JL, et al.: BEAM-alem-tuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity and survival in 65 patients. Blood 103:428-434, 2004.

119. Hubbard SM, Chabner B, DeVita VT Jr, et al.: Histologic progression in non-Hodgkin's lymphoma. Blood 59: 258-264, 1982.

120. Yuen AR, Kamel OW, Halpern J, et al.: Long-term survival after histologic transformation of low-grade follic-ular lymphoma. J Clin Oncol 13:1726-1733, 1995.

121. Schouten HC, Bierman PJ, Vaughn WP, et al.: Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 74:2579-2584, 1989.

How To Bolster Your Immune System

How To Bolster Your Immune System

All Natural Immune Boosters Proven To Fight Infection, Disease And More. Discover A Natural, Safe Effective Way To Boost Your Immune System Using Ingredients From Your Kitchen Cupboard. The only common sense, no holds barred guide to hit the market today no gimmicks, no pills, just old fashioned common sense remedies to cure colds, influenza, viral infections and more.

Get My Free Audio Book

Post a comment